Home ETF List About

ETF Holdings Breakdown of TVTX

Stock NameTravere Therapeutics Inc
TickerTVTX(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS89422G1076

TVTX institutional holdings

The following institutional investment holdings of TVTX have been identified

Date ETF ISIN/Name Num Shares Book value
2025-10-20 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 10,474USD 292,120 2.0%
2025-10-20 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 56,316USD 1,570,653
2025-10-20 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 56,316USD 1,570,653
2025-10-20 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 56,951USD 1,588,363
2025-10-20 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 608USD 16,957
Total =180,665 USD 5,038,746
Book value of shares is calculated on the adjusted close price of each day (row).

News associated with TVTX

HC Wainwright Reaffirms “Buy” Rating for Travere Therapeutics (NASDAQ:TVTX)
Travere Therapeutics (NASDAQ:TVTX – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. They currently have a $47.00 price objective on the stock. HC Wainwright’s price target would suggest a potential upside of 122.22% from the company’s previous close. HC Wainwright also […] - 2025-09-05 05:03:21
Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) has been given an average rating of “Moderate Buy” by the fifteen analysts that are covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and thirteen have issued a buy recommendation on the company. The average twelve-month price target […] - 2025-07-18 04:50:54
Diversified Trust Co Acquires 1,258 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)
Diversified Trust Co raised its holdings in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) by 8.6% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 15,959 shares of the company’s stock after acquiring an additional 1,258 shares during the quarter. Diversified Trust […] - 2025-07-02 05:23:02
Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives $32.14 Consensus Price Target from Analysts
Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the fifteen brokerages that are presently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. The average 1-year price objective among […] - 2025-06-26 02:54:57
Assenagon Asset Management S.A. Sells 116,999 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)
Assenagon Asset Management S.A. lessened its stake in Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) by 22.1% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 413,514 shares of the company’s stock after selling 116,999 shares during the quarter. Assenagon Asset Management S.A. owned about […] - 2025-06-15 05:44:52
Citigroup Has Lowered Expectations for Travere Therapeutics (NASDAQ:TVTX) Stock Price
Travere Therapeutics (NASDAQ:TVTX – Free Report) had its price objective lowered by Citigroup from $35.00 to $32.00 in a research note released on Wednesday, Marketbeat Ratings reports. Citigroup currently has a buy rating on the stock. A number of other research analysts also recently issued reports on TVTX. JPMorgan Chase & Co. boosted their target […] - 2025-06-12 05:30:57
Travere Therapeutics (NASDAQ:TVTX) Coverage Initiated by Analysts at HC Wainwright
HC Wainwright initiated coverage on shares of Travere Therapeutics (NASDAQ:TVTX – Free Report) in a report published on Wednesday morning, MarketBeat.com reports. The brokerage issued a buy rating and a $30.00 price objective on the stock. Several other brokerages have also recently issued reports on TVTX. Scotiabank reissued an “outperform” rating on shares of Travere […] - 2025-06-12 04:56:59
California State Teachers Retirement System Has $1.26 Million Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)
California State Teachers Retirement System lifted its stake in Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) by 10.8% in the fourth quarter, HoldingsChannel reports. The firm owned 72,192 shares of the company’s stock after purchasing an additional 7,041 shares during the period. California State Teachers Retirement System’s holdings in Travere Therapeutics were worth $1,258,000 at […] - 2025-06-10 04:34:56
Universal Beteiligungs und Servicegesellschaft mbH Buys New Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)
Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 253,622 shares of the company’s stock, valued at approximately $4,418,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.32% […] - 2025-06-02 06:28:49
Public Employees Retirement System of Ohio Raises Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)
Public Employees Retirement System of Ohio lifted its stake in Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) by 102.0% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 102,756 shares of the company’s stock after purchasing an additional 51,876 shares during the period. […] - 2025-06-02 05:38:53
ProShare Advisors LLC Buys 6,896 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)
ProShare Advisors LLC raised its holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) by 37.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 25,347 shares of the company’s stock after buying an additional 6,896 shares during the quarter. ProShare Advisors LLC’s holdings in […] - 2025-05-28 04:54:52
Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by Nuveen Asset Management LLC
Nuveen Asset Management LLC lessened its stake in Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) by 4.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,743,190 shares of the company’s stock after selling 88,913 shares during the quarter. Nuveen Asset Management LLC […] - 2025-05-22 06:38:53
Tudor Investment Corp ET AL Has $753,000 Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)
Tudor Investment Corp ET AL grew its holdings in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) by 13.3% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 43,213 shares of the company’s stock after purchasing an additional 5,069 shares […] - 2025-05-08 05:26:55
Wedbush Reaffirms “Outperform” Rating for Travere Therapeutics (NASDAQ:TVTX)
Wedbush reissued their outperform rating on shares of Travere Therapeutics (NASDAQ:TVTX – Free Report) in a research report report published on Friday morning,Benzinga reports. The firm currently has a $30.00 price objective on the stock. A number of other analysts also recently commented on TVTX. Guggenheim reiterated a “buy” rating and set a $47.00 target […] - 2025-05-05 02:28:52
Stifel Nicolaus Issues Positive Forecast for Travere Therapeutics (NASDAQ:TVTX) Stock Price
Travere Therapeutics (NASDAQ:TVTX – Free Report) had its price target increased by Stifel Nicolaus from $22.00 to $23.00 in a research note released on Friday,Benzinga reports. The brokerage currently has a hold rating on the stock. A number of other research firms have also recently issued reports on TVTX. Guggenheim reissued a “buy” rating and […] - 2025-05-05 02:28:52
XTX Topco Ltd Buys 14,928 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX)
XTX Topco Ltd grew its stake in Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) by 105.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,133 shares of the company’s stock after acquiring an additional 14,928 shares during the period. XTX Topco […] - 2025-04-21 05:36:51
Franklin Resources Inc. Invests $631,000 in Travere Therapeutics, Inc. (NASDAQ:TVTX)
Franklin Resources Inc. purchased a new stake in Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) during the fourth quarter, Holdings Channel.com reports. The institutional investor purchased 36,238 shares of the company’s stock, valued at approximately $631,000. Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Geode Capital […] - 2025-04-17 04:38:48
Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $31.00
Travere Therapeutics (NASDAQ:TVTX – Free Report) had its price target increased by Bank of America from $29.00 to $31.00 in a report issued on Tuesday,Benzinga reports. Bank of America currently has a buy rating on the stock. A number of other equities research analysts have also recently commented on the company. Citigroup increased their target […] - 2025-04-02 04:52:51
Bank of New York Mellon Corp Raises Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)
Bank of New York Mellon Corp grew its position in Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) by 3.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 216,863 shares of the company’s stock after acquiring an additional 7,513 shares during the quarter. Bank of […] - 2025-03-19 05:08:45
Los Angeles Capital Management LLC Reduces Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX)
Los Angeles Capital Management LLC decreased its position in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) by 42.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,996 shares of the company’s stock after selling 11,955 shares during the quarter. Los […] - 2025-03-05 08:41:21
Ieq Capital LLC Makes New Investment in Travere Therapeutics, Inc. (NASDAQ:TVTX)
Ieq Capital LLC bought a new stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX – Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 20,749 shares of the company’s stock, valued at approximately $361,000. Other hedge funds have also recently made changes to […] - 2025-02-28 07:19:05
Travere Therapeutics (NASDAQ:TVTX) Stock Price Expected to Rise, Citigroup Analyst Says
Travere Therapeutics (NASDAQ:TVTX – Get Free Report) had its price target upped by equities researchers at Citigroup from $31.00 to $35.00 in a report issued on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Citigroup’s price target suggests a potential upside of 69.49% from the stock’s current price. Other equities research […] - 2025-02-26 04:30:58
Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives $27.77 Average Target Price from Analysts
Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) have earned a consensus rating of “Moderate Buy” from the fourteen analysts that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and thirteen have given a buy recommendation to the company. The average 12-month […] - 2025-02-21 04:46:48
Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $45.00
Travere Therapeutics (NASDAQ:TVTX – Get Free Report) had its target price hoisted by equities researchers at Canaccord Genuity Group from $22.00 to $45.00 in a research report issued on Wednesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity Group’s price objective indicates a potential upside of 89.71% from the stock’s […] - 2025-02-14 05:10:57
Travere Therapeutics Delivers Over 180% Gain In 6 Months
(RTTNews) - For Travere Therapeutics Inc. (TVTX), the year so far has been nothing short of remarkable, with its shares hitting new highs, driven by the success of its oral kidney disease drug, Filspari.Filspari indicated to slow kidney function decline in adults with a kidney di - 2025-02-12 08:29:03

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.